<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DDI-DrugBank.d519">
    <sentence id="DDI-DrugBank.d519.s0" text="No formal drug/drug interaction studies with Plenaxis were performed.">
        <entity charOffset="45-52" id="DDI-DrugBank.d519.s0.e0" text="Plenaxis" type="brand"/>
    <negationtags>&lt;scope&gt; &lt;cue&gt; No &lt;/cue&gt; formal drug/drug interaction studies with Plenaxis were performed. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d519.s1" text="Cytochrome P-450 is not known to be involved in the metabolism of Plenaxis.">
        <entity charOffset="66-73" id="DDI-DrugBank.d519.s1.e0" text="Plenaxis" type="brand"/>
    <negationtags>Cytochrome P-450 is &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; known to be involved in the metabolism of Plenaxis. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d519.s2" text="Plenaxis is highly bound to plasma proteins (96 to 99%).">
        <entity charOffset="0-7" id="DDI-DrugBank.d519.s2.e0" text="Plenaxis" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d519.s3" text="Laboratory Tests Response to Plenaxis should be monitored by measuring serum total testosterone concentrations just prior to administration on Day 29 and every 8 weeks thereafter.">
        <entity charOffset="29-36" id="DDI-DrugBank.d519.s3.e0" text="Plenaxis" type="brand"/>
        <entity charOffset="83-94" id="DDI-DrugBank.d519.s3.e1" text="testosterone" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d519.s3.e0" e2="DDI-DrugBank.d519.s3.e1" id="DDI-DrugBank.d519.s3.p0"/>
    </sentence>
    <sentence id="DDI-DrugBank.d519.s4" text="Serum transaminase levels should be obtained before starting treatment with Plenaxis and periodically during treatment.">
        <entity charOffset="76-83" id="DDI-DrugBank.d519.s4.e0" text="Plenaxis" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d519.s5" text="Periodic measurement of serum PSA levels may also be considered."/>
</document>